Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Patient Reported Outcome Measure in Atopic Dermatitis Patients Treated with Dupilumab: 52-Weeks Results

Version 1 : Received: 16 May 2021 / Approved: 25 May 2021 / Online: 25 May 2021 (09:15:21 CEST)

A peer-reviewed article of this Preprint also exists.

Marron, S.E.; Tomas-Aragones, L.; Moncin-Torres, C.A.; Gomez-Barrera, M.; Aranibar, F.J.-L. Patient Reported Outcome Measure in Atopic Dermatitis Patients Treated with Dupilumab: 52-Weeks Results. Life 2021, 11, 617. Marron, S.E.; Tomas-Aragones, L.; Moncin-Torres, C.A.; Gomez-Barrera, M.; Aranibar, F.J.-L. Patient Reported Outcome Measure in Atopic Dermatitis Patients Treated with Dupilumab: 52-Weeks Results. Life 2021, 11, 617.

Journal reference: Life 2021, 11, 617
DOI: 10.3390/life11070617

Abstract

Dupilumab is used to treat atopic dermatitis patients who have proven to be refractory to previous treatments. The aim of this study was to assess evolution and patient reported outcome measures in adult patients with moderate-to-severe atopic dermatitis treated with Dupilumab in routine clinical practice. The outcomes were evaluated and registered at baseline and weeks-16, 40 and 52. The variables evaluated were: diseases severity, pruritus, stressful life events, difficulty to sleep, anxiety and depression, quality of life, satisfaction, adherence to the treatment, efficacy and safety. Eleven patients were recruited between Nov 14th 2017 and Jan 16th 2018. Demographic variables: 90% Caucasian, 82% women. Clinical variables: Mean duration of AD =17.7 (±12.8), 91% had severe disease severity. At baseline, SCORAD mean score = 61.7 (±15.5); itch was reported by 100% of patients; itch Visual Analogue Scale mean range of 8 (6-10); HADS mean total score =13.9 (±5.5); DLQI mean score =13.3 (±8.3): EQ-5D-3L mean range = 57 (30-99). At week-52 there is a significant reduction of SCORAD scores, HADS total score and improved quality of life. ¡This study confirms that Dupilumab, used for 52-weeks under routine clinical practice, maintains the improved atopic dermatitis signs and symptoms obtained at week-16, with a good safety profile.

Keywords

Atopic dermatitis; Patient Reported Outcome Measures; Dupilumab; Quality of life; Satisfaction; Efficacy; Safety; Adherence

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.